使用Tongxinluo囊 (TXL-CAP) 进行冠状动脉动脉硬性斑块干预:是一项多中心,随机,双盲和安慰剂控制的研究
1State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.
Signal transduction and targeted therapy
|February 24, 2026
概括
传统中国医学Tongxinluo囊疗法,当添加到他类药物时,在急性冠状动脉综合征患者中显著增加了冠状动脉斑块的稳定性. 这种疗法增强了纤维帽的厚度和减少了脂质弧,在12个月内改善了心痛症状.
科学领域:
- 心脏病学 心脏病学
- 传统中国医药 传统中国医药
- 药理学 药理学是指药理学的学科.
背景情况:
- 冠状动脉斑块的脆弱性是急性冠状动脉综合征 (ACS) 的关键因素.
- 对于传统中医 (TCM) 疗法,如Tongxinluo在稳定冠状动脉斑块方面的临床证据有限.
- 立方体治疗是ACS的标准,但需要额外的治疗来改善斑块稳定性.
研究的目的:
- 研究Tongxinluo囊在增加已接受他类药物治疗的ACS患者中冠状动脉斑块稳定性的有效性.
- 评估Tongxinluo对脆弱斑块中纤维盖厚度和脂质弧度大小的影响.
主要方法:
- 进行了一项多中心,随机,双盲,安慰剂对照试验 (TXL-CAP研究).
- 220名患有薄盖脂质丰富斑块的ACS患者 (通过光学连贯性断层扫描 (OCT) 检测到) 被随机分配给Tongxinluo或安慰剂12个月.
- 主要终点是12个月后纤维帽最小厚度的变化.
主要成果:
- 与安慰剂相比,tongxinluo显著增加了纤维状盖的最小厚度 (115.0微米比80.0微米,P<0.001).
- 辛卢组的纤维盖厚度增加更大 (61.2微米 vs 33.7微米,P = 0.002),最大脂质弧度减少更大 (-38.4° vs -8.1°,P = 0.007).
- 接受Tongxinluo的患者报告说,心痛症状有所改善 (西雅图心痛问卷和加拿大心血管学会评分).
结论:
- 作为他类药物治疗的辅助剂,tongxinluo可增强ACS患者的冠状动脉斑块稳定性.
- TCM疗法有效地增加纤维帽厚度,减少脂质弧度大小.
- 辛露可以改善胸痛的症状,这表明它在治疗易受损伤的甲状腺硬化症患者中起到有益的作用.
相关概念视频
01:26Atherosclerosis III: Management
482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
01:27Coronary Artery Disease V: Interprofessional Care
325
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
325
01:26Coronary Artery Disease IV: Preventive Measures
755
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
01:30Atherosclerosis I: Introduction
1.6K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.6K
01:30Acute Coronary Syndrome III: Diagnostic Studies
325
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
325
01:26Angina IV: Management
359
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
359